The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters

Atherosclerosis

Volumn 137, Issue 1, 1998, Pages 77-85

  Nicolosi, Robert J ^a   Wilson, Thomas A ^a   Krause, Brian R ^b  

^a Dept of Health and Clinical Science   (United States)

^b Parke Davis P   (United States)

Author keywords

ACAT inhibitor CI 1011; Anti atherogenic; Cholestyramine; Hypocholesterolemic

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; COLESTYRAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFAMIC ACID ((2,4,6 TRIS (1 METHYLETHYL) PHENYL)ACETYL) 2,6 BIS(1 METHYLETHYL) PHENYL ESTER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HAMSTER; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIPID STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ACETATES; ANIMALS; AORTA; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CRICETINAE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; LIVER; MALE; REFERENCE VALUES; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS; TIME FACTORS; TRIGLYCERIDES;

EID: 0032478324     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00279-7     Document Type: Article

References (38)

1. Suckling KE, Stange EF Role of Acyl-CoA:Cholesterol acyl-transferase in cellular cholesterol metabolism. J Lipid Res. 26:1985;647-671.
2. Norum KR, Lilljeqvist AC, Helgerud P, Normann ER, Mo A, Selbekk B Esterification of cholesterol in human small intestine: the importance of acyl-CoA:cholesterol acyltransferase. Eur J Clin Invest. 9:1979;55-62.
3. Sliskovic DR, Trivedi BK ACAT inhibitors: potential antiatherosclerotic agents. Curr Med Chem. 1:1994;204-225.
4. Sliskovic DR, White AD Therapeutic potential of ACAT inhibitors as lipid-lowering and anti-atherosclerotic agents. Trends Pharmacol Sci. 12:1991;194-199.
5. Hainer JW, Terry JG, Connell JM et al. Effect of the acyl-CoA:cholesterol transferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther. 56:1994;65-74.
6. Harris WS, Dujovne CA, von Bergmann K et al. Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther. 48:1990;189-194.
7. Kathawala FG, Heider JG Acyl-CoA:cholesterol transferase inhibitors and lipid-lipoprotein metabolism. Witiak DT, Newman HAI, Feller DR Antilipidemic Drugs. 1991;Elsevier, Amsterdam.
8. Lee HT, Sliskovic DR, Picard JA et al. Inhibitors of Acyl-CoA:Cholesterol O-Acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J Med Chem. 39:1996;5031-5034.
9. Bocan TMA, Roseburg W, BakMueller S, Lee P, Kuchera S, Lee H. CI-1011, an ACAT inhibitor with paradoxical antiatherosclerotic activity. Twelfth International Symposium on Drugs Affecting Lipid Metabolism 1995;132.
10. Kowala MC, Nunnari JJ, Durham SK, Nicolosi RJ Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters. Atherosclerosis. 91:1991;35-49.
11. Rong N, Ausman LM, Nicolosi RJ Oryzanol decreases cholesterol absorption and aortic fatty streaks in hamsters. Lipids. 32:1997;303-309.
12. Nistor A, Bulla A, Filip DA, Radu A The hyperlipidemic hamster as a model of experimental atherosclerosis. Atherosclerosis. 68:1987;159-173.
13. Terpstra AHM, Holmes JC, Nicolosi RJ The hypocholesterolemic effect of dietary soybean protein versus casein in hamsters fed cholesterol-free or cholesterol-enriched semipurified diets. J Nutr. 121:1991;944-947.
14. Krause BR, Bousley RF, Kieft KA, Stanfield RL Effect of the ACAT inhibitor CI-976 on plasma cholesterol concentrations and distribution in hamsters fed zero- and low-cholesterol diets. Clin Biochem. 25:1992;371-377.
15. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC Enzymatic determination of total serum cholesterol. Clin Chem. 20:1974;470-475.
16. Buccolo G, David H Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 19:1973;476-482.
17. Kieft KA, Bocan TMA, Krause BR Rapid determination of cholesterol distribution among plasma lipoproteins following high-performance gel-filtration chromatography. J Lipid Res. 32:1991;859-866.
18. Krause BR, Schork NJ, Kieft KA, Smith MP, Maciejko JJ High correlation but lack of agreement between direct high-performance gel chromatography analysis and conventional indirect methods for determining lipoprotein cholesterol. Clin Chem. 42:1996;1996-2001.
19. Foxall TL, Shwaery GT, Stucchi AF, Wang SS, Nicolosi RJ Dose-response effects of doxazosin on plasma lipids, lipoprotein cholesterol and aortic fatty streak formation in hypercholesterolemic hamsters. Am J Pathol. 140:1992;1357-1363.
20. Carr TP, andersen CJ, Rudel LL Enzymatic determination of triglycerides, free cholesterol and total cholesterol in tissue lipid extracts. Clin Biochem. 26:1993;39-44.
21. Snedecor GW, Cochran WG. Statistical Methods, Ames, IA: Iowa State University Press, 1990.
22. Bocan TMA, Bakmueller S, Uhlendorf PD, Newton RS, Krause BR Comparison of CI-976, an ACAT inhibitor and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic-aortic lesions. A biochemical, morphological and morphometric evaluation. Arterioscler Thromb. 11:1991;1830-1843.
23. Suckling KE, Benson GM, Bond B et al. Cholesterol lowering and bile acid excretion in the hamster with cholestyramine treatment. Atherosclerosis. 89:1991;183-190.
24. Daggy BP, O'Connell NC, Jerdack GR, Stinson BA, Setchell KDR Additive hypocholesterolemic effect of psyllium and cholestyramine in the hamster: effect on fecal sterol and bile acid profiles. J Lipid Res. 38:1997;56-67.
25. Groot PHE, Pearce NJ, Suckling KE, Eisenberg S Effects of cholestyramine on lipoprotein levels and metabolism in Syrian hamsters. Biochim Biophys Acta. 1123:1992;76-84.
26. Sugiyama Y, Odaka H, Itokawa S, Ishikawa E, Tomari Y, Ikeda H TMP-153 a novel ACAT inhibitor, lowers plasma cholesterol through its hepatic action in golden hamsters. Atherosclerosis. 118:1995;145-153.
27. Jackson B, Gee A, Black S, Suckling KE Effects of octimibate, an inhibitor of acyl-coenzyme A: cholesterol acyltransferase, on cholesterol metabolism in the hamster and rat. Biochem Pharmacol. 39:1990;1487-1489.
28. Murakami S, Ohta Y, Asami Y et al. The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow. Gen Pharmacol. 27:1996;1383-1386.
29. Carr TP, Hamilton RL, Rudel LL ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res. 36:1995;25-36.
30. Krause BR, anderson M, Bisgaier CL et al. In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res. 34:1993;279-294.
31. Burrier RE, Smith AA, McGregor DG, Hoos LM, Zilli DL, Davis HR The effect of acyl-CoA:cholesterol acyl-transferase inhibition on the uptake, esterification and secretion of cholesterol by the hamster small intestine. J Pharmacol Exp Ther. 272:1995;156-163.
32. Balasubramaniam S, Simons LA, Chang S, Roach PD, Nestel PJ On the mechanism by which an ACAT inhibitor (CL 277,082) influences plasma lipoproteins in the rat. Atherosclerosis. 82:1990;1-5.
33. Krause BR, Sliskovic DR, Bocan TMA Emerging therapies in atherosclerosis. Section review: cardiovascular and renal. Exp Opin Invest Drugs. 4:1995;353-387.
34. Krause BR, Auerbach BJ. ACAT inhibition by CI-1011 lowers plasma triglycerides in rats by enhancing the clearance of VLDL. Eleventh Symposium of Atherosclerosis, Paris, Atherosclerosis 1997;134:128 (Abstract 2. p. 55).
35. Packard CJ, Shepherd J The hepatobiliary axis and lipoprotein metabolism: Effects of bile acid sequestrants and ileal bypass surgery (review). J Lipid Res. 23:1982;1081-1098.
36. Benson GM, Alston DR, Bond BC et al. SK&F 97426-A a more potent bile acid sequestrant and hypocholesterolemic agent than cholestyramine in the hamster. Atherosclerosis. 101:1993;51-60.
37. Trautwein EA, Siddiqui A, Hayes KC Modeling plasma lipoprotein-bile lipid relationships: Differential impact of psyllium and cholestyramine in hamsters fed a lithogenic diet. Metabolism. 42:1993;1531-1540.
38. Riddell D, Bright CP, Burton BJ et al. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem Pharmacol. 52:1996;1177-1186.